Carmel Biosciences

6 articles about Carmel Biosciences

• Nutriband Inc. Signs LOI to Acquire Carmel Biosciences

  6/13/2018

  Nutriband Inc. (OTCQB: NTRB), is pleased to announce that it has signed a Letter of Intent to acquire 100% of Carmel Biosciences.

• Medicure Announces an Up-Date on PREXXARTAN Launch

  3/19/2018

  Medicure had intended to launch PREXXARTAN® during the first half of 2018.

• Medicure Announces FDA Approval Received for Prexxartan

  12/20/2017

  The FDA approval of Prexxartan makes it the first and only approved oral liquid dosage form of the ARB valsartan in the United States.

• Medicure Acquires License to Sell and Market PREXXARTAN in the U.S. From Carmel Biosciences

  11/1/2017

  Under terms of the agreement, Medicure obtains exclusive rights in the United States and territories to develop, manufacture and market PREXXARTAN for a seven year term, with potential extensions to the term available.

• Medicure Acquires Exclusive License to Sell and Market PREXXARTAN in the U.S. From Carmel Biosciences

  11/1/2017

  Medicure has acquired an exclusive license to sell and market PREXXARTAN (valsartan) oral solution in the U.S. and its territories from Carme for a seven year term with extensions to the term available.

• Carmel Biosciences Executive Director Receives USA-India Business Award

  6/28/2012